$SEEL
Seelos Therapeutics Inc Stock $seel

$seel Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000101749115000054 Filed on May 11, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$475.0K	$0.00
YoY Change		-100.0%
Cost Of Revenue	$233.0K	$0.00
YoY Change		-100.0%
Gross Profit	$242.0K	$0.00
YoY Change		-100.0%
Gross Profit Margin	50.95%
Selling, General & Admin	$3.100M	$3.060M
YoY Change	1.31%	-20.1%
% of Gross Profit	1280.99%
Research & Development	$3.268M	$1.444M
YoY Change	126.32%	2.19%
% of Gross Profit	1350.41%
Depreciation & Amortization	$74.00K	$20.00K
YoY Change	270.0%	-4.76%
% of Gross Profit	30.58%
Operating Expenses	$6.364M	$3.543M
YoY Change	79.62%	-32.37%
Operating Profit	-$6.122M	-$3.543M
YoY Change	72.79%	-42.49%
Interest Expense	-$158.0K	-$107.0K
YoY Change	47.66%	-53.68%
% of Operating Profit
Other Income/Expense, Net	-$290.0K	$281.0K
YoY Change	-203.2%	-135.61%
Pretax Income	-$6.410M	-$3.260M
YoY Change	96.63%	-53.09%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$6.412M	-$3.262M
YoY Change	96.57%	-62.39%
Net Earnings / Revenue	-1349.89%
Basic Earnings Per Share	-$0.13	-$0.09
Diluted Earnings Per Share	-$0.13	-$0.09
COMMON SHARES
Basic Shares Outstanding	47.63M shares	37.90M shares
Diluted Shares Outstanding	47.63M shares

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.16M	$22.49M
YoY Change	-28.15%	59.5%
Cash & Equivalents	$16.16M	$22.49M
Short-Term Investments
Other Short-Term Assets	$1.150M	$620.0K
YoY Change	85.48%	-36.73%
Inventory	$217.0K	$364.0K
Prepaid Expenses
Receivables	$513.0K	$69.00K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$18.04M	$23.54M
YoY Change	-23.39%	51.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.449M	$1.360M
YoY Change	6.54%	121.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$153.0K	$93.00K
YoY Change	64.52%	-5.1%
Total Long-Term Assets	$1.602M	$1.453M
YoY Change	10.25%	39.04%
TOTAL ASSETS
Total Short-Term Assets	$18.04M	$23.54M
Total Long-Term Assets	$1.602M	$1.453M
Total Assets	$19.64M	$24.99M
YoY Change	-21.43%	50.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$880.0K	$990.0K
YoY Change	-11.11%	-46.49%
Accrued Expenses	$5.016M	$1.979M
YoY Change	153.46%	-47.0%
Deferred Revenue
YoY Change
Short-Term Debt	$530.0K	$2.660M
YoY Change	-80.08%	88.65%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.158M	$14.58M
YoY Change	-50.91%	43.38%
LONG-TERM LIABILITIES
Long-Term Debt	$4.300M	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$302.0K	$80.00K
YoY Change	277.5%	-63.3%
Total Long-Term Liabilities	$302.0K	$80.00K
YoY Change	277.5%	-63.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.158M	$14.58M
Total Long-Term Liabilities	$302.0K	$80.00K
Total Liabilities	$17.97M	$14.66M
YoY Change	22.56%	-14.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$296.3M	-$271.3M
YoY Change	9.19%	4.44%
Common Stock	$297.9M	$280.2M
YoY Change	6.32%	8.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.670M	$8.890M
YoY Change
Total Liabilities & Shareholders Equity	$19.64M	$24.99M
YoY Change	-21.43%	50.31%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$6.412M	-$3.262M
YoY Change	96.57%	-62.39%
Depreciation, Depletion And Amortization	$74.00K	$20.00K
YoY Change	270.0%	-4.76%
Cash From Operating Activities	-$6.127M	-$192.0K
YoY Change	3091.15%	-97.16%
INVESTING ACTIVITIES
Capital Expenditures	$165.0K	$355.0K
YoY Change	-53.52%	859.46%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$50.00K
YoY Change	-100.0%	-98.97%
Cash From Investing Activities	-$165.0K	-$305.0K
YoY Change	-45.9%	-106.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$10.96M	$1.641M
YoY Change	567.7%	107.46%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$11.05M	$1.583M
YoY Change	597.92%	100.38%
NET CHANGE
Cash From Operating Activities	-$6.127M	-$192.0K
Cash From Investing Activities	-$165.0K	-$305.0K
Cash From Financing Activities	$11.05M	$1.583M
Net Change In Cash	$4.756M	$1.086M
YoY Change	337.94%	-194.43%
FREE CASH FLOW
Cash From Operating Activities	-$6.127M	-$192.0K
Capital Expenditures	$165.0K	$355.0K
Free Cash Flow	-$6.292M	-$547.0K
YoY Change	1050.27%	-91.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	apri	Accrued License Fees AccruedLicenseFees	2500000	USD
CY2015Q1	apri	Accrued License Fees AccruedLicenseFees	2500000	USD
CY2014Q1	apri	Increase Decreasein Deferred Rental Incomeand Other Noncurrent Assets IncreaseDecreaseinDeferredRentalIncomeandOtherNoncurrentAssets	2000	USD
CY2015Q1	apri	Increase Decreasein Deferred Rental Incomeand Other Noncurrent Assets IncreaseDecreaseinDeferredRentalIncomeandOtherNoncurrentAssets	3000	USD
CY2014Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	838000	USD
CY2015Q1	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	984000	USD
CY2015Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm	P2Y5M7D
CY2015Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermOne	P3Y9M7D
CY2014Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0360
CY2015Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1154
CY2015Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	6859682	shares
CY2015Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	3.83
CY2015Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2015Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	1.82
CY2014Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.83
CY2015Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.21
CY2015Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice	0.00
CY2014	apri	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms1 SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1	P2Y8M6D
CY2014Q1	apri	Stock Returned From Contract Settlement Shares StockReturnedFromContractSettlementShares	388888	shares
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50414481	shares
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
CY2015Q1	dei	Trading Symbol TradingSymbol	APRI
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	860000	USD
CY2015Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	880000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	678000	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	513000	USD
CY2014Q1	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	59000	USD
CY2015Q1	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	46000	USD
CY2014Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1112000	USD
CY2015Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	550000	USD
CY2014Q4	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	126000	USD
CY2015Q1	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	119000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4555000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5016000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	625000	USD
CY2015Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	991000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	291727000	USD
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	297884000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	42000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	491000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	289000	USD
CY2014Q4	us-gaap	Assets Assets	14809000	USD
CY2015Q1	us-gaap	Assets Assets	19637000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	13289000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	18035000	USD
CY2014Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	70000	USD
CY2015Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2014Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	5000	USD
CY2015Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	3000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21405000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22491000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11400000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16156000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1086000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4756000	USD
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	9881659	shares
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44330006	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50414481	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44330006	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50414481	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	44000	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	50000	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	233000	USD
CY2014Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2015Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	88000	USD
CY2014Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	312000	USD
CY2015Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	268000	USD
CY2014Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	176000	USD
CY2015Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	180000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	41000	USD
CY2015Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	31000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	226000	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	181000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1000000	USD
CY2015Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1000000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	74000	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2015Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5213000	USD
CY2015Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5100000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2015Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	136000	USD
CY2014Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	910000	USD
CY2014	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	900000	USD
CY2015Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	50000	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	0	USD
CY2014Q1	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	50000	USD
CY2015Q1	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	0	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3059000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3096000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	0	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	242000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	67000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-68000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-165000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-203000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	461000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-468000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-562000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4654000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-45000	USD
CY2014Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-393000	USD
CY2015Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-58000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-54000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-55000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	103000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	223000	USD
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	50000	USD
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-10000	USD
CY2014Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-107000	USD
CY2015Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-146000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	275000	USD
CY2015Q1	us-gaap	Inventory Net InventoryNet	217000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	106000	USD
CY2015Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	105000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	169000	USD
CY2015Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	112000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	12890000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	17967000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14809000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19637000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6906000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7158000	USD
CY2014Q1	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2015Q1	us-gaap	Licenses Revenue LicensesRevenue	350000	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4626000	USD
CY2015Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	4294000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1583000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11048000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-305000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-165000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-192000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6127000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-3262000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-6412000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	281000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-290000	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	153000	USD
CY2015Q1	us-gaap	Notes Payable Current NotesPayableCurrent	531000	USD
CY2015Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	3543000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	6364000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3543000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6122000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	290000	USD
CY2015Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	242000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	162000	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	153000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	358000	USD
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	302000	USD
CY2014Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2015Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-12000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	388000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-144000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	355000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	165000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	646000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	869000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1641000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10957000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10900000	USD
CY2014Q1	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	50000	USD
CY2015Q1	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	0	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	83000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1358000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1449000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	8000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1444000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3268000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	290000	USD
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	280000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-289852000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-296264000	USD
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	88000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	37000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	475000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	491000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	289000	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8075
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0196
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0167
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0158
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0139
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	0	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	3021977	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6859682	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	9881659	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	500000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1300000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1200000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.48
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.05
CY2015Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	40000	shares
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	1919000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	1670000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37872179	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47632760	shares

Files In Submission

Name	View Source	Status
0001017491-15-000054-index-headers.html	Edgar Link	pending
0001017491-15-000054-index.html	Edgar Link	pending
0001017491-15-000054.txt	Edgar Link	pending
0001017491-15-000054-xbrl.zip	Edgar Link	pending
apri-20150331.xml	Edgar Link	completed
apri-20150331.xsd	Edgar Link	pending
apri-20150331_cal.xml	Edgar Link	unprocessable
apri-20150331_def.xml	Edgar Link	unprocessable
apri-20150331_lab.xml	Edgar Link	unprocessable
apri-20150331_pre.xml	Edgar Link	unprocessable
apri33115.htm	Edgar Link	pending
apri33115ex103.htm	Edgar Link	pending
apri33115ex311.htm	Edgar Link	pending
apri33115ex312.htm	Edgar Link	pending
apri33115ex321.htm	Edgar Link	pending
apri33115ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEEL
Seelos Therapeutics Inc Stock $seel

2015 Q1 Form 10-Q Financial Statement

#000101749115000054 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL Seelos Therapeutics Inc Stock $seel

2015 Q1 Form 10-Q Financial Statement

#000101749115000054 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL
Seelos Therapeutics Inc Stock $seel